NCT05876117 Premedication for Claustrophobic Patients for MRI Scan
| NCT ID | NCT05876117 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Salem Anaesthesia Pain Clinic |
| Condition | Claustrophobia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2020-07-04 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2020-07-04 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Claustrophobia is an irrational fear of restriction and suffocation. It is a specific phobia, according to DSM 5. Claustrophobic patients may fear that restriction of their limbs will hinder their ability to move quickly towards safety. MRI may trigger claustrophobia, because this diagnostic procedure involves a patient laying in a narrow tube. Premedication before MRI scan may occasionally reduce claustrophobia. Prospective observational crossover study of claustrophobic patients who are undergoing MRI scan. At alternate MRI scan sessions, each patient receives rotational premedication using Lorazepam 1mg; or Clonidine tablet 0.2mg; or combined Clonidine 0.2mg + Lorazepam 1mg. Patient will use Claustrophobia Questionnaire, a validated tool, to collect data on the days before and after each MRI scan. CLQ is a patient-administered tool used to assess claustrophobia. In addition, patient will use General Anxiety Disorder Questionnaire, a validated tool, to collect data on the days before and after each MRI scan. GAD-7 is a patient-administered tool that is used to assess anxiety.
Eligibility Criteria
Inclusion Criteria: * diagnosed with claustrophobia * previous incomplete MRI because of claustrophobia * adult patients * good treatment compliance * reliable Claustrophobia Questionnaire (CLQ) diary * reliable General Anxiety Disorder Questionnaire (GAD) diary * informed consent for diary review * consent for clinical record quality assurance review Exclusion Criteria: * poor treatment compliance * cognitive disorder * inability to provide consent * major neuropsychiatric disorder * unreliable diary * cannabis use * excessive alcohol intake * previous adverse/allergic reactions to clonidine * previous adverse/allergic reactions to lorazepam
Contact & Investigator
Olu Bamgbade, MD,FRCPC
PRINCIPAL INVESTIGATOR
Salem Anaesthesia Pain Clinic
Frequently Asked Questions
Who can join the NCT05876117 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 99 Years, studying Claustrophobia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05876117 currently recruiting?
Yes, NCT05876117 is actively recruiting participants. Contact the research team at salem.painclinic@gmail.com for enrollment information.
Where is the NCT05876117 trial being conducted?
This trial is being conducted at Surrey, Canada.
Who is sponsoring the NCT05876117 clinical trial?
NCT05876117 is sponsored by Salem Anaesthesia Pain Clinic. The principal investigator is Olu Bamgbade, MD,FRCPC at Salem Anaesthesia Pain Clinic. The trial plans to enroll 50 participants.